Work

Supplementary Figure 2 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

Year: 2024

Type: supplementary-materials

Abstract: Supplementary Figure 2. Efficacy of belzutifan monotherapy for pancreatic neuroendocrine tumors. A, Kaplan-Meier curve of progression-free survival for pancreatic neuroendocrine tumors. B, Spider plot showing change from baseline over time in size of target pancreatic neuroendocrine tumors.

DOI: 10.1158/1078-0432.25728547

Authors: Tobias Else, Eric Jonasch, Othon Iliopoulos, Kathryn E. Beckermann, Vivek Narayan, Benjamin L. Maughan, Stephane Oudard, Jodi K. Maranchie, Ane B. Iversen, Cynthia M. Goldberg, Wei Fu, Rodolfo F. Perini, Yanfang Liu, W. Marston Linehan, Ramaprasad Srinivasan

Language: English

Topic: Neuroendocrine Tumor Research Advances

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4396544036

Cites:

Cited by:

Related to: 10